🇺🇸 FDA

Intelligence Platform

Patents

Browse 1,015 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11078266

Anti-human IL-3 antibodies, their use in treatment of a disease or malfunction associated

UNIVERSITÄTSKLINIKUM REGENSBURG · Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11072639

Bi-functional anti-tau polypeptides and use thereof

REGENERATIVE RESEARCH FOUNDATION · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11072656

Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066474

Anti-TrkB monoclonal antibodies and methods of use

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11066378

Caffeic acid derivatives for anti-angiogenesis

China Medical University · Granted Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11059906

Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma

Takeda Pharmaceutical Company Limited · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11058664

In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pe

Provectus Pharmatech, Inc. · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11058802

Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applicati

The Board of Regents of the University of Texas System · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11059896

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11053280

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11034736

Anti-viral cnidarins

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11014983

Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making

Sutro Biopharma, Inc. · Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10995150

Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10981977

Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein

THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10983128

CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy

Providence Health & Services · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10980780

Methods and compositions of anti-inflammatory drug and dicer activator for treatment of ne

NEUROSENSE THERAPEUTICS LTD. · Granted Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975158

CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

The Regents of the University of California · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975139

Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10975150

Anti-CD74 antibodies, compositions comprising anti-CD74 antibodies and methods of using an

Sutro Biopharma, Inc. · Granted Tue Apr 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10966977

Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor

TG Therapeutics, Inc. · Granted Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10961301

Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair

The United States Government represented by the Department of Veterans Affairs · Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10961305

Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Mereo Biopharma 3 Limited · Granted Tue Mar 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10954289

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10947198

Chroman-substituted, tetrahydroquinoline-substituted and thiochroman-substituted heteroaro

The Board of Regents for Oklahoma State University · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted